Viral Infections in HSCT Recipients with Post-Transplant Lymphoproliferative Disorder: The Role of Torque Teno Virus as a Marker of Immune Functions

被引:0
作者
Pociupany, Martyna [1 ]
Tarabella, Carolina [2 ]
Snoeck, Robert [1 ]
Dierickx, Daan [3 ,4 ]
Andrei, Graciela [1 ]
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol Immunol & Transplantat, Mol Struct & Translat Virol Res Grp, B-3000 Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Cardiovasc Sci, Ctr Mol & Vasc Biol, B-3000 Leuven, Belgium
[3] Univ Hosp Leuven, Dept Hematol, B-3000 Leuven, Belgium
[4] Katholieke Univ Leuven, Dept Oncol, Lab Expt Hematol, B-3000 Leuven, Belgium
关键词
post-transplant lymphoproliferative disorder; Torque Teno virus; hematopoietic stem cell transplantation; Epstein-Barr virus; STEM-CELL TRANSPLANTATION; TORQUETENOVIRUS VIREMIA; DYNAMICS; KINETICS; RISK; LOAD;
D O I
10.3390/microorganisms13020326
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Monitoring immune function in post-transplant patients is crucial to reduce the risk of viral infections (e.g., cytomegalovirus [CMV] or Epstein-Barr virus [EBV]), which can lead to serious complications such as post-transplant lymphoproliferative disorder (PTLD). Recently, Torque Teno virus (TTV) has attracted interest as a marker of immune function. Thus, we studied the kinetics of common post-transplant viral infections (TTV, EBV, CMV, human herpesvirus-6 [HHV-6], and adenovirus [AdV]) and their association with clinical parameters in 23 HSCT recipients who developed PTLD (PTLD-HSCT) and 25 post-HSCT patients without PTLD (Non-PTLD-HSCT) at three different timepoints: at the time of the transplant (T0), 3 months (T1), and 6 months (T2) post-HSCT. Additionally, 25 healthy donors (HD) were used as the control. EBV, CMV, HHV-6, or AdV infections were found in a few samples, while TTV was found in all of our samples. The highest TTV levels (4.61 [T0], 6.24 [T1] and 6.70 [T2] log10 copies/mL) were seen in PTLD-HSCT patients compared to Non-PTLD-HSCT (3.39 [T0], 4.86 [T1], and 3.75 [T2] log10 copies/mL) and HD (2.25 log10 copies/mL) at all timepoints. Higher TTV levels were also seen in patients with a destructive type of PTLD and in surviving PTLD-HSCT patients compared to deceased ones. TTV kinetics in PTLD patients post-HSCT showed that TTV levels increase with the fall in the host immunocompetence and that by monitoring TTV kinetics, the immune status of the patient can be monitored.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Association of HLA Polymorphisms with Post-transplant Lymphoproliferative Disorder in Solid-Organ Transplant Recipients
    Reshef, R.
    Luskin, M. R.
    Kamoun, M.
    Vardhanabhuti, S.
    Tomaszewski, J. E.
    Stadtmauer, E. A.
    Porter, D. L.
    Heitjan, D. F.
    Tsai, De E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (04) : 817 - 825
  • [32] Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder
    Kalra, Amit
    Roessner, Cameron
    Jupp, Jennifer
    Williamson, Tyler
    Tellier, Raymond
    Chaudhry, Ahsan
    Khan, Faisal
    Taparia, Minakshi
    Jimenez-Zepeda, Victor H.
    Stewart, Douglas A.
    Daly, Andrew
    Storek, Jan
    CYTOTHERAPY, 2018, 20 (05) : 706 - 714
  • [33] Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines
    Parker, Anne
    Bowles, Kristin
    Bradley, J. Andrew
    Emery, Vincent
    Featherstone, Carrie
    Gupte, Girish
    Marcus, Robert
    Parameshwar, Jayan
    Ramsay, Alan
    Newstead, Charles
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (05) : 675 - 692
  • [34] A Post-transplant Immunosuppression Complication: Epstein-Barr Virus-Positive Classic Hodgkin Lymphoma Post-transplant Lymphoproliferative Disorder
    Zaver, Himesh B.
    Prakash, Gautham
    Plant, Samuel
    Chaudhari, Jigisha
    Erno, Jason
    Mithqal, Ayman
    Courville, Elizabeth
    Marchi, Enrica
    Henry, Zachary
    ACG CASE REPORTS JOURNAL, 2025, 12 (02)
  • [35] Epstein-Barr viral loads do not predict post-transplant lymphoproliferative disorder in pediatric lung transplant recipients: A multicenter prospective cohort study
    Parrish, Andrew
    Fenchel, Matthew
    Storch, Gregory A.
    Buller, Richard
    Mason, Sheila
    Williams, Nikki
    Ikle, David
    Conrad, Carol
    Faro, Albert
    Goldfarb, Samuel
    Hayes, Don, Jr.
    Melicoff-Portillo, Ernestina
    Schecter, Marc
    Visner, Gary
    Sweet, Stuart
    Danziger-Isakov, Lara
    PEDIATRIC TRANSPLANTATION, 2017, 21 (06)
  • [36] Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients
    Köpf, S
    Tönshoff, B
    PEDIATRIC NEPHROLOGY, 2004, 19 (04) : 365 - 368
  • [37] Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder
    Hatton, Olivia
    Martinez, Olivia M.
    Esquivel, Carlos O.
    PEDIATRIC TRANSPLANTATION, 2012, 16 (03) : 220 - 229
  • [38] Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients
    Colombini, Elisa
    Guzzo, Isabella
    Morolli, Federica
    Longo, Germana
    Russo, Cristina
    Lombardi, Alessandra
    Merli, Pietro
    Barzon, Luisa
    Murer, Luisa
    Piga, Simone
    degli Atti, Marta Luisa Ciofi
    Locatelli, Franco
    Dello Strologo, Luca
    PEDIATRIC NEPHROLOGY, 2017, 32 (08) : 1433 - 1442
  • [39] Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation
    Lim, Wai H.
    Russ, Graeme R.
    Coates, Patrick Th
    NEPHROLOGY, 2006, 11 (04) : 355 - 366
  • [40] Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases
    Styczynski, J.
    Einsele, H.
    Gil, L.
    Ljungman, P.
    TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (05) : 383 - 392